Serum-Free Inducer Composition for Estradiol-Secreting Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells are inefficient, complex, and risky, with low induction efficiency, long induction times, and potential genetic changes or cancer risks.
Innovation Solution
An inducer comprising BMP4, BMP7, RA, resveratrol, icariin, benzamide, chloroplatinic acid hexahydrate, ethanolamine, EPO, and VEGF in specific concentration ratios is used in a human mesenchymal stem cell serum-free culture medium to enhance differentiation efficiency and cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional in vitro induction methods are used to differentiate mesenchymal stem cells into estradiol-secreting cells, then differentiation can be achieved, but the induction efficiency is low and the process is complicated
Solution Approach 1:
The patent changes the chemical parameters of the induction system by introducing a small molecule chemical inducer that activates the Wnt/β-catenin signaling pathway. This chemical induction approach replaces complex multi-factor in vitro induction protocols, simplifying the induction process while significantly improving differentiation efficiency to over 80%.
Solution Approach 2:
The patent uses a small molecule chemical inducer as an intermediary substance to activate the Wnt/β-catenin signaling pathway. This intermediary approach indirectly drives mesenchymal stem cell differentiation into estradiol-secreting cells, avoiding the need for direct complex cellular interactions and culture conditions required by traditional methods.
2Productivity
If traditional in vitro induction methods are used, then cell differentiation can occur, but the induction time is excessively long
Solution Approach 1:
By changing the induction mechanism from complex multi-factor stimulation to targeted chemical induction of the Wnt/β-catenin pathway, the patent accelerates the differentiation process. The induction time is reduced from weeks to days, significantly improving productivity while maintaining high differentiation efficiency.
Solution Approach 2:
The chemical inducer directly activates the key signaling pathway responsible for differentiation, allowing the system to skip intermediate stages and accelerate the differentiation process. This rushing through of the induction process reduces time loss while achieving high efficiency differentiation.
3Quantity of substance
If traditional in vitro induction methods are used, then some cells can be obtained, but the number of resulting cells is small and their function is low
Solution Approach 1:
The patent changes the differentiation outcome by targeting the Wnt/β-catenin pathway, which is crucial for germ cell and ovarian follicle development. This pathway activation not only increases the number of differentiated cells to over 80% but also enhances their functional maturity, including estradiol secretion capability and follicle formation potential.
Solution Approach 2:
The chemical inducer acts as an intermediary that mimics physiological signaling, promoting both the quantity and quality of differentiated cells. By activating the Wnt/β-catenin pathway, the inducer ensures that differentiated cells are not only numerous but also functionally mature with proper estradiol secretion and follicle formation capabilities.
4Reliability
If exogenous steroid hormone replacement therapy is used for premature ovarian failure, then symptoms can be improved, but long-term therapy has adverse effects and low recovery efficiency
Solution Approach 1:
The patent enables the patient's own mesenchymal stem cells to differentiate into functional estradiol-secreting cells that can restore ovarian function. This self-service approach allows the body to produce its own hormones through regenerated ovarian tissue, eliminating the need for long-term exogenous hormone replacement therapy and avoiding associated adverse effects.
Solution Approach 2:
The chemical inducer serves as a temporary intermediary to trigger stem cell differentiation into hormone-producing cells. Once differentiation is complete, the inducer is no longer needed, and the patient's own differentiated cells take over hormone production, providing a sustainable solution without long-term external hormone supplementation.
Data Source
AI summary
The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg/L of bone morphogenetic protein-4, 20-60 mg/L of bone morphogenetic protein-7, 2-8 mg/L of retinoic acid, 2-8 mg/L of resveratrol, 2-8 mg/L of icariin, 2-8 µg/L of benzamide, 2-8 µg/L of chloroplatinic acid hexahydrate, 2-8 µg/L of ethanolamine, 2-10 µg/L of erythropoietin and 2-10 µg/L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.